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The hemodynamic effects of Cl-914, a phosphodi- 
esterase inhibitor, were studied in 12 patients with 
left ventricular (LV) dysfunction who were undergo- 
ing diagnostic cardiac catheterization. Cl-914 was 
infused intravenously at a rate of 0.8 to 7.0 
Clg/kg/min for 30 to 80 minutes; hemodynamic vai- 
ues were measured every IO minutes. No effect 
was seen in the patient receiving 0.8 pg/kg/min. At 
infusion rates of 1.2 to 2.4 pg/kg/min, cardiac in- 
dex increased by 14% (p <0.025). At infusion 
rates of 4.5 to 7.0 pg/kg/min, cardiac index in- 
creased by 21% (n = 8, difference not significant 
[NS]). Among 4 patients (group B) with an initial 
pulmonary artery wedge pressure greater than 20 
mm Hg and cardiac index less than 2.5 liters/ 
min/m*, cardiac index increased by 58% (p 
<O.OOl); it did not change among the 4 patients 
with an initial pulmonary artery wedge pressure of 
less than 20 mm Hg and cardiac index of more than 
2.5 iiters/min/m* (group A). Although systemic 
vascular resistance decreased in ail 8 patients by 
28% (p <O.Ol), the reduction was greater in group 
B (33%, p <O.Ol) than in group A (18%, NS). 
Peak -I-dP/dt increased in ail 8 patients by 13 % (p 
<O.Ol). Mean stroke work index increased from 29 
f 15 to 34 f 13 g-m/m*; the double product fell 
from 101 f 31 to 91 f 23 (NS). in ail 12 patients, 
a linear correlation between peak venous blood 
concentration and peak effect on cardiac index, 
systemic vascular resistance and pulmonary artery 
wedge pressure was observed. The increase in car- 
diac index associated with a decrease in systemic 
vascular resistance suggests that part of the favor- 
able hemodynamic effect is attributable to afterload 
reduction. Nonetheless, the increase in peak 
+dP/dt in ail patients suggests that Cl-914 also has 
a positive inotropic effect. This combination of ef- 
fects may be of value in the treatment of severe 
congestive heart failure. 
(Am J Cardioi 1988;58:598-800) 
P hosphodiesterase inhibitors have vasodilator and 
positive inotropic effects and are of value in the acute 
therapy of congestive heart failure (CHF).l-’ Like fi- 
adrenergic agonists,8 phosphodiesterase inhibitors in- 
crease intracellular CAMP, enhance Ca++ flux across 
the slow channel and Ca++ release from the sarcoplas- 
mic reticulum,g-lz exerting a combination of beneficial 
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mechanical effects on myocardium.8 These drugs in- 
crease the peak force developed, the rate of force de- 
velopment and the relaxation velocity, thereby short- 
ening total contraction time and maintaining diastolic 
function despite the tachycardia often associated with 
CHF. Because they act distal to the /3-adrenergic re- 
ceptor, these agents are active even in patients with 
CHF who are relatively insensitive to catechol- 
amines.i3 Moreover, their prolonged use does not ap- 
pear to be associated with development of tachyphy- 
laxis, usually associated with P-adrenergic therapy.14 
CI-914 is a new phosphodiesterase inhibitor selec- 
tive for cAMP.ls It is equipotent with amrinone in 
increasing peak developed tension in rabbit right ven- 
tricular papillary muscle and guinea pig left atrium, 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































598 ACUTE HEMODYNAMIC EFFECTS OF Cl-914 
ing peak +dP/dt after infusion into anesthetized dogs 
despite significant reduction of mean arterial pres- 
sure.l5 As a pyridazinone derivative, chemically dis- 
tinct from the bipyridines, amrinone and milrinone, it 
may not be associated with thrombocytopenia.16 We 
report here the acute hemodynamic effects of CI-914 
on patients with moderate to severe LV dysfunction. 
Methods 
Patients: Twelve patients with symptomatic LV 
dysfunction were studied at diagnostic cardiac cathe- 
terization (Table I]. No patient had primary valvular 
disease, myocardial infarction in the past 2 weeks, nn- 
stable angina, left main coronary artery stenosis or 
clinically significant hepatic or renal disease. All had 
given informed consent to a study protocol approved 
by the University of Michigan Hospital Human Sub- 
ject Review Committee. 
Catheterization protocol: Topical nitrates, calcium 
channel blockers and afterload reducing agents, but 
not diuretic drugs or digoxin, were stopped 24 to 72 
hours before cardiac catheterization. After routine 
right-sided cardiac catheterization and coronary arte- 
riography, baseline hemodynamic variables [heart 
rate, LV pressure with a micromanometer-tip catheter, 
electronically differentiated dP/dt, pulmonary artery, 
pulmonary artery wedge, right atria1 and arterial pres- 
sures, and cardiac output by thermodilution) were 
measured. CI-914 was administered to consecutive pa- 
tients at rates of 0.8 (patient I], 1.2 (patient 2), 2.0 (pa- 
tient 3],2.4 (patient 4), 4.5 (patient 5) and 7.0 pg/kg/min 
(patients 6 through 12) for 60 minutes or unti1 there was 
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FIGURE 1. Dependence of change of stroke work index (SWI) on 
initial pulmonary artery wedge pressure (PCW). The mean f stan- 
dard error of the mean of the initial and final PCW and SWI are 
shown. Closed squares indicate group A control; closed circles, 
group A after drug; open squares, group B control; and open circles, 
group B after drug. 
a decrease in arterial pressure to less than 80 mm Hg or 
a plateau in hemodynamic response. The infusions 
lasted for 60 minutes in patients 1 to 5, 10 and 11; 50 
minutes in patient 7; 40 minutes in patients 6,9 and 12; 
and 30 minutes in patient 8. Cardiac output and pres- 
sures were measured and femoral arterial and venous 
blood samples obtained from the side arms of the fem- 
oral introducer sheaths every 10 minutes during 
the infusion, for 30 minutes after termination of infu- 
sion and 2, 4 and 24 hours after infusion. CI-914 con- 
centration was determined by high-pressure liquid 
chromatography.5 
Analysis of data: Stroke work index was calculated 
as: (mean arterial pressure - LV end-diastolic pres- 
sure) X [stroke volume index] X 0.0136. Double prod- 
uct was calculated as (LV systolic pressure) X (heart 
rate]. The time constant of relaxation (71 was calculat- 
+60 
+40 
CI MAP SVR PCW 
* n n=s 
q PCW<ZOmmHg(n=4) 











FIGURE 2. Systemic and cardiac effects of Cl-914. The peak effect 
of Cl-914 on systemic and cardiac hemodynamic variables are 
expressed as mean percent change from baseline f standard error. 
The hemodynamic effects on patients in groups A and B are shown. 
Level of statistical significance was determined by paired f test on 
the difference between peak change and baseline. l p <O.Ol; “p 
<0.05. Cl = cardiac index; DP = double product; HR = heart rate; 
MAP = mean arterial pressure; PCW = pulmonary capillary wedge 
pressure; SVR = systemic vascular resistance; SWI = stroke work 
index; 7 = time constant of relaxation. 
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ed as the inverse slope of a plot of log pressure vs time 
during isovolumic relaxation beginning at the time of 
peak -dP/dt.17 Because the hemodynamic response of 
patients receiving between 1.2 and 2.4 pg/kg/min dif- 
fered from that of patients receiving a larger dose, 
these patients were analyzed separately. Data are ex- 
pressed as peak response [Table I). In general, the 
peak change in all hemodynamic values occurred 
toward the end of the infusion. 
Results 
No significant hemodynamic effects were observed 
at an infusion rate of 0.8 pg/kg/min. At infusion rates 
of 1.2 to 2.4 pg/kg/min, cardiac index increased by 
14% (n = 3, p <0.025), and systemic vascular resistance 
was reduced to the same degree (n = 3, p <O.O5). Peak 
+dP/dt did not increase significantly (Table I). At in- 
fusion rates of 4.5 to 7.0 pg/kg/min, cardiac index of 
the 8 patients increased from 2.4 f 0.8 to 2.9 f 0.7 
liters/min/mz and stroke work index from 29 f 15 to 34 
f 14 g-m/m2; however, these effects were not uniform. 
In 4 patients with a pulmonary artery wedge pressure 
of less than 20 mm Hg (patients 6 through 9, group A), 
cardiac index and stroke work index did not change 
significantly (from 3.1 f 0.5 to 3.1 f 0.7 liters/m/m2 
and from 42 f 7 to 43 f 5 g-m/m2, respectively] (Fig. 1 
and 2, Table I). In contrast, in 4 patients with a pulmo- 
nary artery wedge pressure of more than 20 mm Hg 
(patients 5, 10, 11 and 12, group B), both cardiac and 
stroke work indexes increased (from 1.8 f 0.4 to 2.7 
f 0.7 liters/min/mz, p <O.Ol, and 15 f 4 to 23 f 5 
g-m/mz, p <O.Ol). In group B systemic vascular resis- 
tance fell more than in group A (32% vs 16%, p <O.Ol), 
as did LV end-diastolic pressure (71% vs 3670, p 
<O.Ol). The double product decreased more among 
patients in group B (16%, p <O.Ol] than in group A 
(470, difference not significant [NS]). Ejection frac- 
tion was 30 f 11% in group A and 20 f 11% in group 
B (NS). 
Peak +dP/dt increased from 744 f 232 to 852 f 263 
mm Hg/s in the 8 patients in groups A and B (p <O.Ol], 
despite variable changes in heart rate and despite a 
decrease in diastolic arterial pressure. Peak -dP/dt 
rose from 729 f 175 to 826 f 211 mm Hg s-l (n = 7, p 
<0.05), and 7 was reduced from 75 f 6 to 48 f 10 s-l (n 
= 8, p <O.Ol). 
Among all 12 patients receiving the drug, the peak 
increase in cardiac index correlated with peak venous 
drug concentration (Fig. 3) (r = 0.58, p <O.Ol). There 
was a better correlation of peak venous plasma level 
with the decrease in pulmonary artery wedge pressure 
(r = -0.69, p <O.Ol] than with the decrease in systemic 
vascular resistance (r = -0.52, p (0.01). The peak val- 
ues of other parameters [pulmonary artery pressure, 
peak +dP/dt and -dP/dt, and 7) did not significantly 
correlate with venous plasma level. The change in 
venous levels of the drug after infusion did not follow 
first-order kinetics. In 2 patients with venous drug con- 
centrations of less than 100 rig/ml, the drug concentra- 
tion dropped to half its initial value at the end of infu- 
sion over the next 2 hours. In 10 patients with venous 
drug levels above 100 rig/ml, drug concentration fell to 
half its initial value after 5 hours. 
Discussion 
These findings suggest that CI-914 administered at 
rates of 1.2 pg/kg/min or more improves the hemody- 
namic state of patients with severe CHF primarily by 
reducing systemic vascular resistance. Among patients 
who responded, systemic vascular resistance fell by 
3370, LV end-diastolic pressure remained optimal, 
and, consequently, stroke volume index increased 
32%. Among patients who did not respond, the initial 
systemic vascular resistance was not significantly ele- 
vated; LV end-diastolic pressure decreased to levels 
not optimal to maintain LV filling; and stroke volume 
index decreased by 16%. The fact that the group with a 
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FIGURE 3. Peak changes of cardiac index (Cl), systemic vascular 
resistance (SVR) and pulmonary artery wedge pressure (PCW) as a 
percent of the baseline value vs peak venous plasma concentration 
of Cl-914. Regression equations are: Percent change of Cl = 0.092 
[Cl-9141 - 5.46; r = 0.56; n = 12; p <O.Ol. Percent change of 
systemic vascular resistance = -0.60 [Cl-9141 - 1.46; r = 0.52; n 
= 12; p <0.05. % change of pulmonary artery wedge = -0.13 [Cl- 
9141 + 0.067; r = -0.67; n = 12; p (0.01. 
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worse ejection fraction (group B) responded better to 
the drug underscores the value of the drug as a vasodi- 
later; those with a poorer ejection fraction had an ini- 
tial hemodynamic state that was more responsive to 
vasodilatation than those of the nonresponders. 
The positive inotropic effect of CI-914 contributed 
to its beneficial effect. Peak +dP/dt increased in all 
patients receiving at least 1.2 pg/kg/min, without an 
effect on heart rate or on arterial diastolic pressure, 
variables that may themselves alter peak +dP/dt,l* 
and despite a significant reduction in LV end-diastolic 
pressure, suggesting an upward shift in the Starling 
curve. Systolic function may have improved as a result 
of improved diastolic function, as observed with mil- 
rinone treatment.6 These effects are comparable to 
those reported by Jafri et al7 and those reported for 
other phosphodiesterase inhibitors.z-5 
The reduction in the systolic double product ob- 
served among responders reflects a reduction in myo- 
cardial oxygen consumption.lg The effect of reduction 
of the range of working LV pressure on myocardial 
oxygen consumption more than offset the higher ener- 
gy cost of an increase in volume work.20921 
Thus, similar to other vasodilators, CI-914 converts 
pressure work to volume work and thereby improves 
cardiac index while reducing myocardial oxygen 
consumption. 
Although CI-914 and other phosphodiesterase in- 
hibitors have acute beneficial effects in patients with 
CHF, the long-term effectiveness and safety must be 
questioned.22p23 Nonetheless, the results of the present 
investigation and of studies of other phosphodiester- 
ase inhibitors suggest that these agents will play an 
important role in the therapy of patients with severe 
LV dysfunction. 
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